Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 medications have risen in popularity.

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

Zepbound, from drugmaker Eli Lilly, belongs to a new class of medications, called GLP-1 agonists, that have skyrocketed in popularity in the U.S. in recent years.

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

Eli Lilly’s weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030 ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.